The treatment of acute venous thromboembolism (VTE) is being completely modified with
the development of direct oral anticoagulants (DOACs). Rivaroxaban, apixaban and …

Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute
treatment of venous thromboembolism (VTE) as well as practical considerations when using …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
For decades, low molecular weight heparins (LMWH) and vitamin K-antagonists have been …

In recent years, several direct‐acting oral anticoagulants (DOAC) have become available for
use in Europe and other regions in indications related to prophylaxis and treatment of …

The advent of direct oral anticoagulants (DOACs) has revolutionized anticoagulation
management in both stroke prevention and venous thromboembolism (VTE) …

Venous thromboembolism (VTE) is a prevalent, potentially fatal health problem. Although
standard anticoagulant therapy is effective when compared with the newer direct oral …

Introduction Acute venous thromboembolism (VTE) is a common disease associated to
significant morbidity and mortality. Materials and methods We systematically reviewed and …

Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare
expenditure. In the United States, approximately 0.1% of the population experiences an …

The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban,
and edoxaban, are poised to replace warfarin for treatment of the majority of patients with …

Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE and deep
vein thrombosis (DVT) are considered expressions of the same disease, termed as venous …